Background: Florzolotau (APN-1607) tau-PET has shown distinct patterns of binding in patients with AD and 4-repeat tauopathies. We aimed to establish disease-specific tau covariance patterns in AD and PSP/CBS and validate them as user-independent quantitative biomarkers for reference-region-free evaluation of tau-PET in an independent clinical cohort.
Method: We analyzed Florzolotau PET data from four different cohorts.
Background: Florzolotau (APN-1607) tau-PET has shown distinct patterns of binding in patients with AD and 4-repeat tauopathies. We aimed to establish disease-specific tau covariance patterns in AD and PSP/CBS and validate them as user-independent quantitative biomarkers for reference-region-free evaluation of tau-PET in an independent clinical cohort.
Method: We analyzed Florzolotau PET data from four different cohorts.
Cerebral atrophy is a key finding in patients with dementia and usually determined on MRI. We tested whether cerebral atrophy can be imaged with FDG PET by applying deformation-based morphometry (DBM). We retrospectively identified 26 patients with a biomarker-supported clinical diagnosis of Alzheimer's disease (AD) who had received FDG PET on a fully-digital PET/CT system and structural MRI and compared them to 13 healthy elderly controls (HEC).
View Article and Find Full Text PDFIdentification of patients with idiopathic normal pressure hydrocephalus (iNPH) in a collective with suspected neurodegenerative disease is essential. This study aimed to determine the metabolic spatial covariance pattern of iNPH on FDG PET using an established technique based on scaled subprofile model principal components analysis (SSM-PCA).We identified 11 patients with definite iNPH.
View Article and Find Full Text PDF